Beyfortus®: Made with All Infants in Mind to Protect Against RSV
Up to 75% of RSV-associated hospitalisations occur in healthy and full-term children.2 Recent studies have shown that nirsevimab provided up to 90% protection against hospitalisation from severe RSV LRTI in infants during their first RSV season.3
Understanding RSV: Disease Burden and Nirsevimab’s Efficacy
In Singapore, RSV circulates all-year round and causes significant paediatric health and economic burden.2 This highlights the need and importance of RSV immunisation to reduce the burden of disease.2